中国神经再生研究(英文版) ›› 2015, Vol. 10 ›› Issue (10): 1591-1593.doi: 10.4103/1673-5374.167751

• 观点:脊髓损伤修复保护与再生 • 上一篇    下一篇

伊马替尼在脊髓损伤中的转化应用

  

  • 收稿日期:2015-09-17 出版日期:2015-10-28 发布日期:2015-10-28
  • 基金资助:

    瑞典脑基金会,瑞典研究理事会(K2012-62X-3185-42-4 ; LO) ,瑞典战略研究基金会,Wings for Life,SSMF,瑞典创新系统机构(VINNOVA)ERC高级研究员补助金(322744; LO) ,卡罗林斯卡医学院StratNeuro基金

Repositioning imatinib for spinal cord injury

Jacob Kjell*, †, Lars Olson   

  1. Department of Neuroscience, Karolinska Institutet, Stockholm,
    Sweden
  • Received:2015-09-17 Online:2015-10-28 Published:2015-10-28
  • Contact: Jacob Kjell, Ph.D., jacob.kjell@ki.se, jacob.kjell@med.uni-muenchen.de.
  • Supported by:

    Work discussed herein was supported by grants from the Swedish Brain Foundation, the Swedish Research Council (K2012-62X-03185-42-4; to LO), Swedish Foundation for Strategic Research, Wings for Life, SSMF, the Swedish Agency for Innovation Systems (VINNOVA), an ERC Advanced Investigator grant (322744; to LO), the StratNeuro initiative, Karolinska Institutet Research Foundations and the Karolinska Institutet DPA program.

摘要:

脊髓的损伤很少会痊愈,因为损伤的神经细胞并不能再生,而较长的神经纤维的再生长往往会被瘢痕组织及神经内部的分子过程所妨碍,来自瑞典卡罗琳学院的研究者通过进行动物实验发现,癌症药物伊马替尼或可促进动物机体的神经再生及运动机能的改善。作者认为伊马替尼可能通过与PDGFR-α结合,抑制p38MAPK信号通路的激活,使该信号通路下游ATF-2的表达和磷酸化水平下降,MMP-9活性降低,减少MMP-9对紧密连接蛋白的降解,保护血脊髓屏障来治疗急性脊髓损伤。

Abstract:

There are currently a number of drugs in clinical trial or close to it, several of them repositioned. In imatinib we believe we have found an additional promising therapeutic candidate, together with candidate efficacy biomarkers. Previous trials have proved the challenge is daunting. Nevertheless, taking all current approaches into account, there is now room for cautious optimism that there will be drugs available in the not too distant future, able to dampen the lasting effects of acute spinal cord damage.